NOVACEA INITIATES CLINICAL STUDY OF DN-101

A A

Novacea has announced the initiation of ASCENT-2, its pivotal Phase III clinical study evaluating the combination of the company's novel oral anticancer agent, DN-101, and Taxotere (docetaxel) in men with prostate cancer for whom hormonal therapy is no longer working, also known as androgen-independent prostate cancer.

The randomized, controlled, multinational study is seeking to enroll approximately 900 patients at over 125 medical centers in the U.S., Europe, and Canada. Prostate cancer is the second leading cause of cancer U.S. in 2005.